| NRG-GY007 | A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
| Closed to Accrual | I/II | >Gynecologic [GY] | Ovarian |
| NRG-BN013 | Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) Versus Fractionated SRS (fSRS) For Intact Brain Metastases | Open to Accrual | III | >Brain [BN] | Other |
| NRG-CC012CD | Managing Symptoms and Psychological Distress During Oral Anti-Cancer Treatment | Open to Accrual | Other | >Cancer Care Delivery Research [CD] | Other |
| NRG-GY032 | A Phase II Study of Tailored Adjuvant Therapy in POLE-Mutated and p53-wildtype/NSMP Early-Stage Endometrial Cancer (RAINBO BLUE & TAPER)
| Open to Accrual | II | >Gynecologic [GY] | Uterine Corpus |
| EAY191-N5 | Molecular Analysis for Combination Therapy Choice (ComboMATCH) EAY191-N5: A Randomized Trial of Neratinib, a Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors A ComboMATCH Treatment Trial
| Open to Accrual | II | >Gynecologic [GY] | Multiple |
| NRG-CC011 | NRG-CC011: Cognitive Training For Cancer Related Cognitive Impairment in Breast Cancer Survivors: A Multi-Center Randomized Double-Blinded Controlled Trial
| Open to Accrual | Other | >Symptom Management [CC] | Other |
| NRG-GY033 | A Phase II Study of Androgen Receptor (AR) Inhibition by Darolutamide in combination with Leuprolide Acetate and Exemestane in Recurrent Adult-Type Ovarian Granulosa Cell Tumors
| Temporarily Closed to Accrual | II | >Gynecologic [GY] | Ovarian |
| NRG-HN011 | A Randomized Phase II Study of Nivolumab versus Nivolumab and BMS-986016 (Relatlimab) as Maintenance Treatment after First-line Treatment with Platinum-Gemcitabine-Nivolumab for Patients with Epstein-Barr Virus-Associated Recurrent/Metastatic Nasopharyngeal Carcinoma (REMAIN) | Open to Accrual | II | >Head and Neck [HN] | Head and Neck |
| NRG-GU013 | The Phase III ‘High Five Trial’ Five Fraction Radiation For High-Risk Prostate Cancer | Open to Accrual | III | >Genitourinary [GU] | Prostate |
| NRG-BR009 | A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score ≤ 25 (OFSET) | Open to Accrual | III | >Breast [BR] | Breast |
| NRG-GY031 | A Phase IB Study Of Combination Atr (M1774) And Bet Inhibition (Zen003694) To Exploit Arid1a Loss In Recurrent Ovarian And Endometrial Cancer
| Open to Accrual | I/II | >Gynecologic [GY] | Uterine Corpus |
| NRG-LU008 | Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer | Open to Accrual | III | >Lung [LU] | Non-small Cell Lung Cancer |
| NRG-BR008 | NRG-BR008: A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer (HERO) | Open to Accrual | III | >Breast [BR] | Breast |
| EAY191-N2 | EAY191-N2: Phase 2 Trial of Fulvestrant and Binimetinib in Patients With Hormone Receptor-Positive Metastatic Breast Cancer With a Frameshift or Nonsense Mutation or Genomic Deletion in NF1
| Open to Accrual | II | >Breast [BR] | Breast |
| EAY191-N4 | Molecular Analysis for Combination Therapy Choice (ComboMATCH) EAY191-N4: A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers - A ComboMATCH Treatment Trial
| Open to Accrual | II | >Gynecologic [GY] | Multiple |
| NRG-GY028 | A Phase IB and Randomized Phase II trial of Megestrol Acetate with or without Ipatasertib in Recurrent or Metastatic Endometrioid Endometrial Cancer
| Open to Accrual | I/II | >Gynecologic [GY] | Uterine Corpus |
| NRG-HN010 | A Controlled, Randomized Phase II Trial of Docetaxel Plus Trastuzumab Versus Ado-Trastuzumab Emtansine for Recurrent, Metastatic, or Treatment-Naïve, Unresectable Her2-Positive Salivary Gland Cancer | Open to Accrual | II | >Head and Neck [HN] | Head and Neck |
| NRG-CC010 | A Phase III Trial of the Impact of Sentinel Lymph Node Mapping On Patient Reported Lower Extremity Limb Dysfunction in Endometrial Cancer
| Open to Accrual | III | >Gynecologic [GY] | Uterine Corpus |
| NRG-BN012 | A Randomized Phase III Trial Of Pre-Operative Compared To Post-Operative Stereotactic Radiosurgery In Patients With Resectable Brain Metastases | Open to Accrual | III | >Brain [BN] | Brain Mets |
| NRG-GY026 | A Phase II/III Study Of Paclitaxel/Carboplatin Alone Or Combined With Either Trastuzumab And Hyaluronidase-Oysk (Herceptin Hylecta) Or Pertuzumab, Trastuzumab, And Hyaluronidase-Zzxf (Phesgo) In Her2 Positive, Stage I-Iv Endometrial Serous Carcinoma Or Carcinosarcoma
| Open to Accrual | II/III | >Gynecologic [GY] | Uterine Corpus |
| NRG-GY029 | A Randomized Phase II trial comparing the combination of PI3K inhibitor Copanlisib (BAY 80-6946) and PARP inhibitor Olaparib (AZD2281) to standard chemotherapy in patients with recurrent platinum resistant ovarian, fallopian tube, or primary peritoneal cancer who have progressed through prior PARP inhibitor therapy
| Closed to Accrual | II | >Gynecologic [GY] | Ovarian |
| NRG-GY027 | NRG-GY027: PHASE I/IB SAFETY AND PHARMACODYNAMIC STUDY OF NEOADJUVANT (NACT) PACLITAXEL AND CARBOPLATIN WITH IPATASERTIB AS INITIAL THERAPY OF OVARIAN CANCER PTMA 100805
| Open to Accrual | I | >Gynecologic [GY] | Ovarian |
| NRG-GU012 | Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) For Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (Samurai) | Open to Accrual | II | >Genitourinary [GU] | Other |
| NRG-GI008 | Colon Adjuvant Chemotherapy based on Evaluation of Residual Disease (CIRCULATE-NORTH AMERICA) | Open to Accrual | II/III | >Gastrointestinal [GI] | Colorectal |
| NRG-GY025 | NRG-GY025: A RANDOMIZED PHASE II TRIAL OF NIVOLUMAB AND IPILIMUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN PATIENTS WITH DEFICIENT MISMATCH REPAIR SYSTEM RECURRENT ENDOMETRIAL CARCINOMA
| Open to Accrual | II | >Gynecologic [GY] | Uterine Corpus |
| NRG-GU011 | A Phase II Double-Blinded, Placebo Controlled Trial of Prostate Oligometastatic Radiotherapy with or without Androgen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean) | Open to Accrual | II | >Genitourinary [GU] | Prostate |
| NRG-BN011 | A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma | Open to Accrual | III | >Brain [BN] | Malignant Glioma |
| NRG-HN009 | Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100 mg/m2) Every Three Weeks versus Radiation with Low-Dose Weekly Cisplatin (40 mg/m2) for Patients with Locoregionally Advanced Squamous Cell Carcinoma of The Head And Neck (SCCHN) | Open to Accrual | II/III | >Head and Neck [HN] | Head and Neck |
| NRG-CC005 | Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps | Open to Accrual | III | >Prevention [CC] | Colorectal |
| NRG-GU010 | Parallel Phase III Randomized Trials Of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And Intensification Clinical Trial Evaluation (Guidance) | Open to Accrual | III | >Genitourinary [GU] | Prostate |
| NRG-GY024 | Groningen International Study on Sentinel Nodes in Vulvar Cancer (GROINSS-V) III: A Prospective Phase II Treatment Trial | Open to Accrual | II | >Gynecologic [GY] | Cervix |
| NRG-BN010 | A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma | Closed to Accrual | I/II | >Brain [BN] | Other |
| NRG-BR007 | A Phase III Clinical Trial evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score Less than or Equal to 18: The DEBRA Trial | Open to Accrual | III | >Breast [BR] | Breast |
| NRG-GY023 | A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab | Closed to Accrual | II | >Gynecologic [GY] | Ovarian |
| GOG-0268 | A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: 683864, IND #61010) in Combination with Carboplatin and Paclitaxel followed by Temsirolimus Consolidation as First-line Therapy in the Treatment of Clear Cell Carcinoma of the Ovary. | Closed to Accrual | II | >Gynecologic [GY] | Ovarian |
| NRG-CC009 | Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or Fewer Brain Metastases from Small Cell Lung Cancer | Open to Accrual | III | >Symptom Management [CC] | Other |
| NRG-HN008 | Phase I Trial With Expansion Cohort of DNA-PK Inhibition and IMRT In Cisplatin-Ineligible Patients with Stage 3-4 Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) | Open to Accrual | I | >Head and Neck [HN] | Head and Neck |
| NRG-GU009 | Parallel Phase III Randomized Trials For High Risk Prostate Cancer Evaluating De-Intensification For Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (Predict-RT*) *Prostate RNA Expression/Decipher To Individualize Concurrent Therapy with Radiation | Open to Accrual | III | >Genitourinary [GU] | Prostate |
| EA8185 | ECOG-ACRIN/NRG Joint Study:A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, the INSPIRE Study | Closed to Accrual | II | >Genitourinary [GU] | Bladder |
| NRG-LU007 | RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial | Open to Accrual | II/III | >Lung [LU] | Small Cell |
| NRG-BN007 | A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide In Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma | Closed to Accrual | II/III | >Brain [BN] | Malignant Glioma |
| NRG-CC008 | A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk] | Open to Accrual | Other | >Prevention [CC] | Ovarian |
| NRG-HN006 | Randomized Phase II/III Trial Of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection For Early-Stage Oral Cavity Cancer | Open to Accrual | II/III | >Head and Neck [HN] | Head and Neck |
| NRG-GI007 | Phase I Trial with Expansion Cohort of OBP-301 (Telomelysin) and Definitive Chemoradiation for Patients with Locally Advanced Esophageal And Gastroesophageal Adenocarcinoma Who are Not Candidates for Surgery | Closed to Accrual | I | >Gastrointestinal [GI] | Esophageal |
| S1914 | SWOG/NRG Joint Study: A Randomized Phase III Trial of Induction/ Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC | Closed to Accrual | III | >Lung [LU] | Non-small Cell Lung Cancer |
| S1806 | SWOG/NRG Joint Study: Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer | Closed to Accrual | III | >Genitourinary [GU] | Bladder |
| NRG-GU008 | Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) *INtensifying treatment for NOde positive prostate cancer by VArying the hormonal ThErapy | Open to Accrual | III | >Genitourinary [GU] | Prostate |
| NRG-GY020 | A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed, Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer | Closed to Accrual | III | >Gynecologic [GY] | Uterine Corpus |
| NRG-GI005 | Phase II/III Study of Circulating tumOr DNA as a Predictive BiomaRker in Adjuvant Chemotherapy in Patients with Stage IIA
Colon Cancer (COBRA)
| Closed to Accrual | II/III | >Gastrointestinal [GI] | Colorectal |
| NRG-GY021 | A Phase II Randomized Trial of Olaparib versus Olaparib plus Tremelimumab in Platinum-Sensitive Recurrent Ovarian Cancer | Closed to Accrual | II | >Gynecologic [GY] | Ovarian |
| NRG-GY022 | Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin | Open to Accrual | I | >Gynecologic [GY] | Other |
| NRG-GY019 | A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum | Open to Accrual | III | >Gynecologic [GY] | Ovarian |
| GOG-0274 RTOG 1174 | A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: THE OUTBACK TRIAL | Closed to Accrual | III | >Gynecologic [GY] | Cervix |
| NRG-GY018 | A PHASE III RANDOMIZED, PLACEBO-CONTROLLED STUDY OF PEMBROLIZUMAB (MK-3475, NSC #776864) IN ADDITION TO PACLITAXEL AND CARBOPLATIN FOR MEASURABLE STAGE III OR IVA, STAGE IVB OR RECURRENT ENDOMETRIAL CANCER | Closed to Accrual | III | >Gynecologic [GY] | Uterine Corpus |
| NRG-GY014 | A Phase II Study of Tazemetostat (EPZ-6438) (IND # 138671) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma | Closed to Accrual | II | >Gynecologic [GY] | Ovarian |
| NRG-GU006 | A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy with or without Enhanced Anti-Androgen Therapy with Apalutamide in Recurrent Prostate Cancer | Closed to Accrual | II | >Genitourinary [GU] | Prostate |
| GOG-0237 | Comparative Analysis of CA-IX, p16, Proliferative Markers, and Human Papilloma Virus (HPV) in the Diagnosis of Significant Cervical Lesions in Patients with a Cytologic Diagnosis of Atypical Glandular Cells (AGC) | Closed to Accrual | I | >Gynecologic [GY] | Cervix |
| NRG-GY012 | A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women with Recurrent, Persistent or Metastatic Endometrial Cancer.: A Platform Trial for Women with Recurrent or Persistent Endometrial Cancer | Closed to Accrual | II | >Gynecologic [GY] | Uterine Corpus |
| NRG-GU007 | Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I) | Closed to Accrual | I/II | >Genitourinary [GU] | Prostate |
| RTOG-1112 | Randomized Phase III Study of Sorafenib versus Stereotactic Body Radiation Therapy followed by Sorafenib in Hepatocellular Carcinoma | Closed to Accrual | III | >Gastrointestinal [GI] | Liver |
| NRG-HN005 | A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients with Early-Stage, p16-Positive, Non-Smoking Associated Oropharyngeal Cancer | Closed to Accrual | II/III | >Head and Neck [HN] | Head and Neck |
| NRG-LU003 | A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Master Protocol | Closed to Accrual | II | >Lung [LU] | Non-small Cell Lung Cancer |
| NRG-DT001 | A Phase Ib Trial of Neoadjuvant AMG-232 Concurrent with Preoperative Radiotherapy in Wild-Type P53 Soft Tissue Sarcoma (STS) | Closed to Accrual & Treatment | I | >Other [DT] | Sarcoma |
| RTOG-0924 | Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial | Closed to Accrual | III | >Genitourinary [GU] | Prostate |
| NRG-LU005 | Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab | Closed to Accrual | III | >Lung [LU] | Small Cell |
| NRG-LU002 | Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy For Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial | Closed to Accrual | II/III | >Lung [LU] | Non-small Cell Lung Cancer |
| NRG-GU003 | A Randomized Phase III Trial Of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT) | Complete | III | >Genitourinary [GU] | Prostate |
| NRG-BR005 | A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment without Surgery | Complete | II | >Breast [BR] | Breast |
| NRG-CC003 | A Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer | Closed to Accrual | II/III | >Symptom Management [CC] | Other |
| NSABP B-55 BIG 6-13 | OlympiA: A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy | Closed to Accrual & Treatment | III | >Breast [BR] | Breast |
| RTOG-0534 | A Phase III Trial of Short Term Androgen Deprivation With Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients With a Rising PSA After Radical Prostatectomy | Closed to Accrual | III | >Genitourinary [GU] | Prostate |
| NRG-LU004 | Phase I Trial of Radiotherapy Combined With Durvalumab Alone Plus Either Monalizumab or Oleclumab in PD-L1 High Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (ARCHON-1) | Temporarily Closed to Accrual | I | >Lung [LU] | Non-small Cell Lung Cancer |
| RTOG-0815 | A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy with or without Short-Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate Cancer | Closed to Accrual | III | >Genitourinary [GU] | Prostate |
| NRG-CC007CD | Increasing the Dose of Survivorship Care Planning in Prostate Cancer Survivors Who Receive Androgen Deprivation Therapy | Closed to Accrual | II | >Cancer Care Delivery Research [CD] | Other |
| NRG-HN004 | Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin | Closed to Accrual & Treatment | II/III | >Head and Neck [HN] | Head and Neck |
| NRG-BR004 | A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer | Closed to Accrual | III | >Breast [BR] | Breast |
| GOG-0213 | A Phase III Randomized Controlled Clinical Trial Of Carboplatin and Paclitaxel or Gemcitabine) Alone or in Combination with Bevacizumab (NSC #704865, IND #113912) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrenovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865, IND #113912) | Closed to Accrual | III | >Gynecologic [GY] | Ovarian |
| NRG-GI006 | Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer | Open to Accrual | III | >Gastrointestinal [GI] | Esophageal |
| NSABP B-39 RTOG 0413 | A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer | Complete | III | >Breast [BR] | Breast |
| NSABP B-40 | A Randomized Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel when Administered Before AC with or without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR with Each of the Regimens | Complete | III | >Breast [BR] | Breast |
| NRG-GY006 | A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer | Closed to Accrual | III | >Gynecologic [GY] | Cervix |
| NRG-GY005 | A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS). | Closed to Accrual | II/III | >Gynecologic [GY] | Ovarian |
| NRG-GY004 | A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Closed to Accrual | III | >Gynecologic [GY] | Ovarian |
| NRG-GU005 | Phase III IGRT and SBRT versus IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer | Closed to Accrual | III | >Genitourinary [GU] | Prostate |
| NRG-LU001 | Randomized Phase II Trial of Concurrent Chemoradiotherapy +/- Metformin HCL in Locally Advanced NSCLC | Closed to Accrual | II | >Lung [LU] | Non-small Cell Lung Cancer |
| NRG-HN001 | Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA) | Closed to Accrual | II/III | >Head and Neck [HN] | Head and Neck |
| GOG-0278 | Evaluation of Physical Function and Quality of Life (QOL) Before and After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy with Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 (</= 2 cm) Cervical Cancer | Closed to Accrual | I/II | >Gynecologic [GY] | Cervix |
| NRG-GY017 | Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently with Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer | Closed to Accrual | I | >Gynecologic [GY] | Cervix |
| RTOG-1308 | Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC | Closed to Accrual | III | >Lung [LU] | Non-small Cell Lung Cancer |
| NRG-GI003 | A Phase III Randomized Trial of Protons Versus Photons for Hepatocellular Carcinoma | Open to Accrual | III | >Gastrointestinal [GI] | Liver |
| NRG-BN003 | Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma | Open to Accrual | III | >Brain [BN] | Benign Brain Tumors |
| NRG-BN005 | A Phase II Randomized Trial of Proton vs. Photon Therapy (IMRT) for Cognitive Preservation in Patients with IDH Mutant, Low to Intermediate Grade Gliomas. | Closed to Accrual | II | >Brain [BN] | Lower Grade Glioma |
| NRG-GY003 | A Phase II Randomized Trial of Nivolumab with or without Ipilimumab in Patients with Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer | Closed to Accrual | II | >Gynecologic [GY] | Ovarian |
| NRG-GI002 | A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer | Closed to Accrual | II | >Gastrointestinal [GI] | Anal Canal |
| AGCT1531 | A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors | Open to Accrual | III | >Gynecologic [GY] | Other |
| NRG-BR002 | A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer | Closed to Accrual | II/III | >Breast [BR] | Breast |
| GOG-0225 | Can Diet and Physical Activity Modulate Ovarian or Primary Peritoneal Cancer Progression-Free Survival? | Closed to Accrual | III | >Gynecologic [GY] | Ovarian |
| NRG-GY009 | A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab (IND #134427) Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer | Closed to Accrual | II/III | >Gynecologic [GY] | Ovarian |
| NSABP B-37 IBCSG 27-02 | A Randomized Clinical Trial of Adjuvant Chemotherapy for Radically Resected Loco-Regional Relapse of Breast Cancer | Closed to Accrual & Treatment | III | >Breast [BR] | Breast |
| RTOG-0828 | Pilot Project to Reduce Missing RTOG Quality of Life Data Via Electronic Web-Based Form Collection: A Companion Study for RTOG 0415 (A Phase III Randomized Study of Hypofractionated 3D-CRT/IMRT Versus Conventionally Fractionated 3D-CRT/IMRT in Patients wi | Closed to Accrual | III | >Genitourinary [GU] | Prostate |
| RTOG-1115 | Phase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) with a GnRH Agonist vs. Dose Escalated Radiation Therapy and Enhanced ADT with a GnRH Agonist and TAK-700 for Men with High Risk Prostate Cancer | Closed to Accrual | III | >Genitourinary [GU] | Prostate |
| RTOG-0834 | Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma: The CATNON Intergroup Trial | Closed to Accrual | III | >Brain [BN] | Benign Brain Tumors |
| RTOG-9110 | NCCTG 86-72-51: A Phase III Evaluation of Postoperative Radiation in Low Grade Intracranial Astrocytomas and Oligodendrogliomas | Closed to Accrual | III | >Brain [BN] | Other |
| RTOG-0848 | A Phase IIR and a Phase III Trial Evaluating Both Erlotinib (Ph IIR) And Chemoradiation (Ph III) As Adjuvant Treatment For Patients With Resected Head Of Pancreas Adenocarcinoma | Closed to Accrual | II/III | >Gastrointestinal [GI] | Pancreas |
| RTOG-1016 | Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer | Closed to Accrual | III | >Head and Neck [HN] | Head and Neck |
| RTOG-1005 | A Phase III Trial Of Accelerated Whole Breast Irradiation With Hypofractionation Plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost For Early-Stage Breast Cancer | Closed to Accrual | III | >Breast [BR] | Breast |
| GOG-0263 | Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA, Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphdenectomy. | Closed to Accrual | III | >Gynecologic [GY] | Cervix |
| NSABP B-47 | A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer | Complete | III | >Breast [BR] | Breast |
| NRG-GI004/SWOG-S1610 | Colorectal Cancer Metastatic dMMR/MSI-H Immuno-therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-high (MSI-H) Metastatic Colorectal Cancer | Open to Accrual | III | >Gastrointestinal [GI] | Colorectal |
| GOG-0281 | A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients with Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer | Closed to Accrual | II/III | >Gynecologic [GY] | Ovarian |
| RTOG-0920 | A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer | Closed to Accrual | III | >Head and Neck [HN] | Head and Neck |
| NSABP NCIC CTG MA.32.F | Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer | Complete | III | >Breast [BR] | Breast |
| NSABP B-52 | A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) With or Without Estrogen Deprivation | Complete | III | >Breast [BR] | Breast |
| NSABP B-51 RTOG 1304 | A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy | Closed to Accrual | III | >Breast [BR] | Breast |
| NSABP B-49 | A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer | Closed to Accrual | III | >Breast [BR] | Breast |
| NSABP B-43 | A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy | Closed to Accrual | III | >Breast [BR] | Breast |
| NSABP B-42 | A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer | Closed to Accrual & Treatment | III | >Breast [BR] | Breast |
| NRG-BR003 | A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer | Closed to Accrual | III | >Breast [BR] | Breast |
| NRG-HN002 | A Randomized Phase II Trial for Patients with p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer | Closed to Accrual | II | >Head and Neck [HN] | Head and Neck |
| GOG-0286B | A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer | Closed to Accrual | II/III | >Gynecologic [GY] | Uterine Corpus |
| RTOG-1008 | A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors | Closed to Accrual & Treatment | II/III | >Head and Neck [HN] | Head and Neck |
| RTOG-0724 | Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy | Closed to Accrual | III | >Gynecologic [GY] | Ovarian |
| RTOG-1216 | Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck | Open to Accrual | II/III | >Head and Neck [HN] | Head and Neck |
| NRG-BN001 | Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma | Closed to Accrual | II | >Brain [BN] | Malignant Glioma |